Zacks Research Issues Pessimistic Estimate for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Research analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research report issued on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings of $0.85 per share for the quarter, down from their previous forecast of $1.02. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q1 2026 earnings at $0.80 EPS, Q3 2026 earnings at $0.98 EPS and Q4 2026 earnings at $1.02 EPS.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.11. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business had revenue of $355.35 million for the quarter, compared to analysts’ expectations of $352.57 million. During the same quarter in the previous year, the business posted $0.77 EPS. Merit Medical Systems’s revenue for the quarter was up 9.8% on a year-over-year basis.

MMSI has been the topic of several other research reports. Raymond James cut their target price on Merit Medical Systems from $116.00 to $108.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Robert W. Baird cut their target price on Merit Medical Systems from $111.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Barrington Research cut their target price on Merit Medical Systems from $111.00 to $103.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Wells Fargo & Company set a $106.00 target price on Merit Medical Systems and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, Piper Sandler cut their target price on Merit Medical Systems from $116.00 to $112.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 23rd. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $108.67.

Merit Medical Systems Trading Up 1.3%

NASDAQ MMSI opened at $98.83 on Monday. The stock has a market capitalization of $5.84 billion, a price-to-earnings ratio of 48.45, a PEG ratio of 2.34 and a beta of 0.70. The stock’s 50 day moving average price is $96.75 and its two-hundred day moving average price is $100.60. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems has a 52 week low of $80.02 and a 52 week high of $111.45.

Hedge Funds Weigh In On Merit Medical Systems

Several large investors have recently bought and sold shares of the company. Maverick Capital Ltd. bought a new position in shares of Merit Medical Systems during the first quarter worth about $134,517,000. Nuveen LLC bought a new position in shares of Merit Medical Systems during the first quarter worth about $80,679,000. Norges Bank bought a new position in shares of Merit Medical Systems during the fourth quarter worth about $66,638,000. Raymond James Financial Inc. bought a new position in shares of Merit Medical Systems during the fourth quarter worth about $48,926,000. Finally, FMR LLC raised its position in shares of Merit Medical Systems by 31.6% during the fourth quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier’s stock worth $200,833,000 after acquiring an additional 499,193 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors.

Insider Transactions at Merit Medical Systems

In other news, CFO Raul Jr. Parra sold 12,451 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the sale, the chief financial officer now directly owns 24,201 shares of the company’s stock, valued at approximately $2,391,300.81. This represents a 33.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $105.31, for a total value of $526,550.00. Following the sale, the director now directly owns 4,657 shares in the company, valued at approximately $490,428.67. This trade represents a 51.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,132 shares of company stock worth $11,139,521 in the last 90 days. Corporate insiders own 3.20% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.